评估新型狂犬病暴露后预防方案或疫苗
本文回顾了人用狂犬病疫苗从神经组织疫苗到细胞培养疫苗的发展,指出高效疫苗仍因直接和间接成本难以普及。文章总结了SAGE工作组和WHO人员在推荐新型一周皮内接种方案(2-2-2-0-0)时所评估的具体标准,包括成本效果、剂次、血清阳转、效力、安全性和患者随访。
要点
- 细胞培养技术使狂犬病疫苗高效且耐受良好,减少了剂量和剂次。
- 暴露后预防成本包括生物制品直接成本及旅行、误工等间接成本。
- WHO推荐新方案时评估了成本效果、剂次、血清阳转、效力、安全性和随访。
核心结论
- 高效细胞培养狂犬病疫苗仍对许多高风险患者不可负担,暴露后预防成本包括直接和间接费用。
- SAGE工作组和WHO人员基于成本效果、剂次、血清阳转、效力、安全性和患者随访等标准评估并推荐了新的一周皮内接种方案(2-2-2-0-0)。
研究设计与样本
- 本文为综述,总结了SAGE工作组和WHO人员为推荐新型狂犬病暴露后预防方案所评估的特定标准。
主要发现
- 细胞培养技术使狂犬病疫苗高效且耐受良好,减少了暴露后挽救生命所需的剂量和剂次。
- 暴露后预防成本不仅包括狂犬病生物制品和设备的直接成本,还包括患者因旅行、误工和住宿产生的间接成本。
关键数值与推荐
- 评估标准包括成本效果、剂次数量、接种后血清阳转、效力、安全性和患者随访。
- 推荐的新方案为一周皮内接种方案(2-2-2-0-0)。
临床怎么用
- 在推荐或选用狂犬病暴露后预防方案时,应综合评估成本效果、剂次、免疫应答、效力、安全性和患者随访等标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of human rabies vaccines has evolved dramatically from the first crude nerve tissue vaccine produced then administered in the presence of Louis Pasteur in 1885. New cell culture technology has enabled highly potent and well-tolerated rabies vaccines to be produced that have reduced the volume and number of doses required to save human lives after exposure. However, these highly potent vaccines are still unaffordable to many patients living at risk of exposure on a daily basis. The cost of post-exposure prophylaxis (PEP) is not only related to the direct cost of rabies biologicals and equipment but is also associated with indirect costs that patients incur as a result of travel, loss of work time (income loss), and accommodation over the period of time that a PEP regimen requires to be completed. This paper summarizes the particular criteria that the SAGE Working Group and WHO personnel reviewed as part of the evaluation process for recommending the new one-week intradermal vaccination regimen (2-2-2-0-0) for rabies post-exposure prophylaxis. These criteria included: Cost-effectiveness; evaluation of number of doses; seroconversion after vaccination; efficacy; safety; and patient follow-up.
引用
- Tarantola A, Tejiokem MC, Briggs DJ, et al. Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines. Vaccine. 2018. PMID: 30471958. doi:10.1016/j.vaccine.2018.10.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。